✨ Free AI Report
Personalis, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Personalis, Inc.
Company Research

Personalis, Inc.: Business Overview, Financials & Competitive Analysis

Personalis, Inc. scores 5/10 on the AskCyborg Cyborg Score (Mixed). High-risk, high-reward opportunity in precision oncology with viable long-term potential pending path to profitability and MRD market adoption. Personalis demonstrates strong technological differentiation and analyst backing (6 buy ratings), but faces profitability challenges with negative EPS of -0.83 and negative free cash flow of -$41.74 million. Revenue growth momentum at.

What is Personalis, Inc.'s industry? Personalis, Inc. (personalis.com) operates in Precision Oncology / Genomic Diagnostics. AskCyborg classifies Personalis, Inc. under Precision Oncology / Genomic Diagnostics in its company registry.

Personalis is a precision oncology genomics company that develops and markets advanced cancer genomic tests and liquid biopsy solutions. The company specializes in whole genome and exome sequencing combined with advan...

5/ 10Mixed

Cyborg Score thesis

High-risk, high-reward opportunity in precision oncology with viable long-term potential pending path to profitability and MRD...

Read the full analyst-debate transcript →
Industry Precision Oncology / Genomic Diagnostics
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Personalis, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Personalis, Inc.

AskCyborg analysts argue the bull and bear cases for Personalis, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Personalis, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Personalis, Inc. Overview

Pro stress-test →

Personalis is a precision oncology genomics company that develops and markets advanced cancer genomic tests and liquid biopsy solutions. The company specializes in whole genome and exome sequencing combined with advanced analytics to deliver comprehensive insights into tumor genetics and immune response, supporting cancer detection, monitoring, and therapy development.

Strategic Profile

Pro stress-test →

Personalis is positioned at the intersection of cancer diagnostics and personalized medicine, with differentiation through its whole genome sequencing approach and proprietary platforms like ImmunoID NeXT and NeXT Personal. The company leverages strategic partnerships with pharmaceutical giants and academic institutions to drive biomarker discovery and expand its addressable market in minimal residual disease (MRD) detection and precision cancer vaccine development.

Competitive Landscape

Pro stress-test →

Personalis competes in the precision oncology genomics market against other liquid biopsy and cancer genomics companies. Its whole genome sequencing differentiation contrasts with exome-only competitors. Key competitive advantages include established CLIA-certified laboratory, partnerships with major pharma firms and VA Million Veterans Program, and proprietary algorithms for tumor microenvironment analysis.

Industry Context

Personalis, Inc. operates in Precision Oncology / Genomic Diagnostics.

Key facts

Headquarters: Fremont, California · Revenue: $65.0M (2022 annual)

What the analysts stress-tested

The top findings that survived the multi-agent debate for Personalis, Inc..

  • Core competitive advantage derives from whole genome sequencing approach versus exome-only competitors, providing more comprehensive genomic data across ~20,000 human genes plus immune system analysis
  • Recent partnership with Indivumed (2025) to build one of the most comprehensive multiomics cancer databases strengthens drug discovery platform
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • March 2026Company presenting at TD Cowen 46th Annual Healthcare Conference in Boston
  • Early 2025Partnership announcement with Indivumed GmbH to combine genomics capabilities with multiomics cancer database
  • +1 moreTrack every material event for Personalis, Inc. as it happens. Explore monitoring →
Get alerted when Personalis, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Guardant Health platformsctDNA-based liquid biopsy for cancer monitoring and detection→Foundation Medicine genomic profilingComprehensive genomic profiling for cancer treatment guidance→Invitae genomic testingBroad genomic sequencing for genetic disease and cancer→

Compare Personalis, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Personalis, Inc. operates in Precision Oncology / Genomic Diagnostics. See how the rest of the sector scores on the Cyborg framework.

Browse Precision Oncology / Genomic Diagnostics research →
NEW · MCP server

Ask your AI assistant about Personalis, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Personalis, Inc. and its top competitor on Cyborg Score”
“What did Personalis, Inc. do this quarter?”
“Is Personalis, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Personalis, Inc. do?+
Personalis is a precision oncology genomics company that develops and markets advanced cancer genomic tests and liquid biopsy solutions. The company specializes in whole genome and exome sequencing combined with advan...
What is Personalis, Inc.'s Cyborg Score?+
Personalis, Inc. has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Personalis, Inc.'s main competitors?+
Named competitors include Guardant Health platforms, Foundation Medicine genomic profiling, Invitae genomic testing. The full competitive landscape is in the AskCyborg report.
How can I get the full Personalis, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Personalis, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Personalis, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Precision Oncology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Revolution Medicines, Inc.8Tyra Biosciences, Inc.7Erasca, Inc.6Acrivon Therapeutics, Inc.5Personalis, Inc.4PMV Pharmaceuticals, Inc.